AbbVie Inc. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: AbbVie delivered strong Q1 FY2026 revenue growth of 12.4% to $15.0B, but net income fell 46.0% to $695M, driven by elevated costs and below-the-line charges, even as operating cash flow surged 134.2% to $3.83B.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue rose 12.4% year-over-year to $15.0B in Q1 FY2026, up from $13.3B in the prior-year period, reflecting continued momentum across AbbVie's diversified pharmaceutical portfolio following the Allergan integration and growth in newer immunology and oncology assets.
Despite operating income growing 6.9% to $4.0B, net income dropped sharply by 46.0% to $695M (vs. $1.29B prior year), suggesting significant below-the-line charges such as interest expense, acquired IPR&D, or tax items that weighed heavily on the bottom line.
Operating margin contracted modestly from 28.0% to 26.6% year-over-year, as SG&A expenses grew 8.7% to $3.58B and cost of revenue rose 5.4% to $4.22B, outpacing revenue growth on a proportional basis.
Revenue
$15B
++12.43% YoY
EPS (Basic)
$0.39
-45.83% YoY
Operating Income
$3.99B
++6.88% YoY
Add ABBV to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.